Bionano Announces Preliminary 3Q 2024 Revenues and Cash
BNGO 10.10.2024

About Gravity Analytica
Recent News
- 01.22.2025 - Bionano Announces Effective Date of Reverse Stock Split
- 01.14.2025 - Bionano Announces Use of OGM in Preimplantation Genetic Testing as Part of Successful Live Birth to a Couple Experiencing Recurrent Pregnancy Loss
- 01.13.2025 - Bionano Reports Preliminary Fourth Quarter and Full-Year 2024 Results
Recent Filings
Cash, cash equivalents, available-for-sale securities, and restricted cash were approximately $23.3 million as of September 30, 2024, of which $11.4 million was subject to certain restrictions.
The Company has not completed its standard quarterly accounting procedures in connection with its end-of-period review and therefore these results and any guidance remain preliminary and subject to further adjustment, including for potential impairments, write downs, and other non-cash or cash charges which may affect the Company’s third quarter 2024 financial results. Such adjustments could be material.
About Bionano
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its
For more information, visitwww.bionano.comorwww.bionanolaboratories.com.
Except as specifically noted otherwise, Bionano’s products are for research use only and not for use in diagnostic procedures.
Forward-Looking Statements of
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “ability,” “believe,” “potential,” “will,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, third quarter 2024 revenue, potential impairments, write downs, and other non-cash or cash charges which may affect the Company’s third quarter 2024 financial results and growth in the Company’s core business. Each of these forward-looking statements involves risks and uncertainties.
Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include adjustments to our preliminary measures of financial performance resulting from, among other things, the completion of our end-of-period review and reporting processes; the impact of adverse geopolitical and macroeconomic events, such as recent and future bank failures, the ongoing
CONTACTSCompany Contact:
Investor Relations:

Source: Bionano Genomics